What are the precautions when using mobosetinib?

Mobotinib, also known as moboxetinib, is an oral small moleculeEGFRkinase inhibitor, mainly used to treat patients with EGFRPatients with non-small cell lung cancer (NSCLC) with exon20insertion mutations, especially those who have progressed after prior systemic therapy. As a new type of targeted drug, the safety and rationality of mobotinib need to be paid close attention to during its use. The following are several aspects that need to be paid attention to when using this drug.

1. Pre-drug genetic testing and patient screening

Mobotinib's mechanism of action is to target EGFRexon20 insertion mutations, so before starting the drug, it must be clarified whether the patient carries this specific mutation through NGS (next generation sequencing) or other molecular testing technology. This is a prerequisite for judging whether the drug is suitable for use. In addition, Mobotinib is not suitable for patients with common EGFR mutations (such as L858R or exon 19 deletions), and is not recommended for the treatment of lung cancer without EGFR mutations. Therefore, the accuracy and timeliness of genetic testing are critical to developing treatment plans.

When evaluating drug suitability, it is also necessary to consider the patient's general condition, liver and kidney function, and previous treatment history, especially whether other EGFR targeted drugs or chemotherapy drugs have been used. If the patient has severe cardiopulmonary dysfunction, active hepatitis or renal insufficiency, it should be used with caution and closely monitored during treatment.

2. Monitoring of adverse reactions during treatment

Common adverse reactions of mobotinib include diarrhea, rash, nausea, vomiting, decreased appetite, and fatigue. Among them, diarrhea is one of the most common side effects that may affect patients' quality of life. Some patients may have moderate to severe diarrhea, which may even lead to dehydration, electrolyte imbalance, etc. Early detection and intervention with antidiarrheal drugs are required.

In addition, Mobotinib may also cause cardiotoxicity such as prolongation of the QT interval and abnormal electrocardiogram. Therefore, regular electrocardiogram examinations are required during the medication, especially patients with underlying cardiac diseases need to be more vigilant. Abnormal liver function is also one of the adverse reactions worthy of attention. Liver enzyme levels should be checked regularly during medication. Once ALT or AST is found to be significantly elevated, medication needs to be suspended or the dosage reduced.

It is worth mentioning that although the incidence of pulmonary toxicity such as interstitial lung disease (ILD) is low, once it occurs, it may be life-threatening. Pay attention to whether patients have symptoms such as unexplained cough, dyspnea, or abnormal lung imaging. If there are suspected signs of ILD, the drug should be discontinued immediately and appropriate treatment should be taken.

3. Identification and management of drug interactions

Mobotinib is metabolized by the CYP3A enzyme, so you need to pay attention to interactions with CYP3A related drugs during use. Simultaneous use with potent CYP3A inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampicin, carbamazepine) should be avoided, otherwise the metabolism of mobotinib in the body may be affected, resulting in fluctuations in drug efficacy or enhanced toxicity.

If patients need to use such drugs together, they should evaluate the risks and benefits under the guidance of a doctor, and adjust the dosage of mobotinib or replace with a suitable drug alternative if necessary. In addition, grapefruit juice should be consumed with caution while taking mobotinib, as it may inhibit CYP3A activity, thereby affecting drug concentration.

4. Usage recommendations and individualized management for special groups of people

Particular caution should be exercised when using mobotinib in the elderly, patients with hepatic and renal impairment, or patients who are underweight. Although there is currently no clear data indicating that the starting dose needs to be adjusted in this population, since they have poor drug tolerance and are more prone to adverse reactions, the dose should be adjusted individually based on clinical manifestations.

For women of childbearing potential, effective contraceptive measures should be taken while using mobotinib, and the drug is prohibited to be used during pregnancy. Animal experiments have shown that the drug may cause toxic effects on the fetus, so it is not recommended for breastfeeding women. If pregnancy is discovered during treatment, the doctor should be informed immediately, and the doctor will evaluate whether to continue taking the medication.

In summary, as a targeted drug targeting EGFR exon 20 insertion mutations, mobotinib provides a new treatment option for some patients with refractory lung cancer. However, adequate attention needs to be paid to the management of adverse reactions, prevention of drug interactions, and individualized treatment of special groups during its use. Patients should use medications scientifically under the guidance of professional doctors and undergo regular check-ups to maximize treatment benefits while ensuring safety.

References：https://en.wikipedia.org/wiki/Mobocertinib